



ATTORNEY DOCKET NO. 09172.0006U1
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
)	
Samuel Christian)	Art Unit: 1623
)	
Application No. 10/625,645)	Examiner: Leigh C. Maier
)	
Filing Date: July 22, 2003)	Confirmation No. 9726
)	
For: PHARMACEUTICAL DOPAMINE)	
GLYCOCONJUGATE COMPOSITIONS)	
AND METHODS OF THEIR)	
PREPARATION AND USE)	

INFORMATION DISCLOSURE STATEMENT

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer Number 23859

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Information Disclosure Statement List is a listing of documents known to Applicants and/or their attorneys. In accordance with 37 C.F.R. §1.98(a)(2), copies of any cited U.S. patent or U.S. patent application publication documents are not enclosed. Some of the documents cited were cited by or submitted to the Patent Office in one or more of Application No. 10/198,798, filed July 18, 2002, abandoned; Application No. 09/547,501, filed April 12, 2000, abandoned; and 09/547,506, filed April 12, 2000, now U.S. Patent No. 6,548,484, all of to which the present application claims priority. Such documents are indicated by an asterisk (*) on

ATTORNEY DOCKET NO. 09172.0006U1
Application No. 10/625,645

the Information Disclosure Statement List. Pursuant to 37 C.F.R. § 1.98(d), copies of these documents are not enclosed. A copy of each of the remaining foreign patent or non-patent documents is enclosed.

In accordance with the provisions of M.P.E.P. § 2001.06(b) and 37 C.F.R. § 1.98(b)(3), Applicants would like to bring to the attention of the Examiner the existence of the co-pending patent application(s) identified below, which were filed in the United States Patent and Trademark Office:

	<u>Application No.</u>	<u>Date Filed</u>	<u>Inventors</u>	<u>Attorney Docket No.</u>
1.	11/343,266 *	01/30/2006	Christian	09172.0003U2

The pending application(s) identified with an asterisk (*) are stored in the Image File Wrapper (IFW) system of the USPTO. Accordingly, copies of the cited specification(s), including the claims and drawings thereof, are not enclosed in accordance with the waiver to 37 CFR 1.98(a)(2)(iii) dated September 21, 2004.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(b)(4), in that a first Office Action on the merits of the present patent application has not yet been mailed to Applicants following the Request For Continued Examination Under 37 C.F.R. § 1.114, filed concurrently herewith.


Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

ATTORNEY DOCKET NO. 09172.0006U1
Application No. 10/625,645

No fee is believed due; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,


NEEDLE & ROSENBERG, P.C.


D. Brian Shortell, JD, PhD
Registration No. 56,020

NEEDLE & ROSENBERG, P.C.
Customer Number 23859
(678) 420-9300
(678) 420-9301 (fax)

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.


D. Brian Shortell, JD, PhD

13 August 2007
Date



INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/625,645
	Filing Date	July 22, 2003
	First Named Inventor	Samual Christian
	Group Art Unit	1623
	Examiner Name	Leigh C. Maier

U.S. PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
	A1*	3,929,813	December 30, 1975	Bodor	546	261	
	A2*	3,962,447	June 8, 1976	Bodor	424	263	
	A3	5,380,837	January 10, 1995	Nakada et al.	536	17.9	
	A4	5,639,737	June 17, 1997	Rubin	514	53	
	A5*	6,339,064	January 15, 2002	McDevitt et al.	514	42	
	A6	6,548,484	April 15, 2003	Christian	514	25	
	A7	2006/0189547	August 24, 2006	Christian	514	23	
Examiner Signature:				Date Considered:			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FOREIGN PATENT DOCUMENTS					
Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No
	A8*	WO 97/28174	August 7, 1997	Oehrlein	
	A9*	WO 01/97244	October 25, 2007	Christian	
Examiner Signature:			Date Considered:		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

NON-PATENT DOCUMENTS		
Examiner's Initials	Cite No.	Non-Patent Citations (Include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)
	A10*	Alexander et al., "Role of conjugation and red blood cells for inactivation of circulating catecholamines," <i>Am. J. Physiol.</i> 247(1):R203-R207 (1984)
	A11*	Alvarado et al., "Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine, in vitro," <i>Biochim. Biophys. Acta</i> 56:170-172 (1960)
	A12*	Arita et al., "Studies on uptake of phenyl glycosides as inhibitors of D-glucose uptake by Rhesus monkey kidney cells," <i>J. Biochem.</i> 88:1399-1406 (1980)
	A13*	Barnett et al., "Structural requirements for binding to the sugar transport system of the human erythrocyte," <i>Biochem. J.</i> 131:211-221 (1973)
	A14*	Barnett et al., "Highlights of D1 dopamine receptor antagonist research," <i>Neurochem. Int.</i> 20 (Suppl.):119S-122S (1992)
	A15*	Bencsics et al., "Dopamine, as well as, norepinephrine, is a link between noradrenergic nerve terminals and splenocytes," <i>Brain Res.</i> 761(2):236-243 (1997)

Examiner Signature:		Date Considered:	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/625,645
	Filing Date	July 22, 2003
	First Named Inventor	Samual Christian
	Group Art Unit	1623
	Examiner Name	Leigh C. Maier

A16*	Berger et al., "Synthesis and receptor affinities of some conformationally restricted analogues of the dopamine D1 selective ligand (5R)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl- 1 H-3-benzazepin-7-ol," <i>J. Med.</i> (1989)
A17*	Brewster et al., "trans-10,11-dihydroxy-5,6,7,8,12b-hexahydrobenzo[a]phen -anthridine: A highly potent selective dopamine D1 full agonist," <i>J. Med. Chem.</i> 33:1756-1764 (1990)
A18*	Bodor et al., "Elimination of a quaternary pyridinium salt delivered as its dihydropyridine," <i>J. Pharr. Sci.</i> 67(5):685 (1978)
A19*	Bodor, "Novel Approaches for the Design of Membrane Transport Properties of Drugs" In: "Design of Biopharmaceutical Properties Through Prodrugs and Analogs", Ed. E.B. Roche et al. APhA Academy of Pharmaceutical Sciences, Washington, D.C., p. 98-135 (1976)
A20*	Bodor et al., "Site-specific, sustained release of drugs to the brain," <i>Science</i> 214:1370-1372 (1981)
A21*	Bodor et al., "Redox delivery systems for brain-specific, sustained release of dopamine," <i>Science</i> 221:65-67 (1983)
A22*	Casagrande et al., "Synthesis and chemical properties of Ibopamine and of related esters of N-substituted dopamines: Synthesis of Ibopamine metabolites," <i>Arzneim.Forsch.</i> 36(2a):291-303 (1986)
A23*	Chen et al., "Transport-dependent accessibility of a cytoplasmic loop cysteine in human dopamine transporter" <i>J. Biol. Chem.</i> 275(3):1608-1614 (2000)
A24*	Choi et al., "Novel 3-aminomethyl and 4-aminopiperidine analogues of 1[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: Synthesis and evaluation as dopamine transporter ligands," <i>J. Med. Chem.</i> 43(2):205-213 (2000)
A25*	Clarkson et al., "Immortalized dopamine neurons: A model to study neurotoxicity and neuroprotection," <i>Proc. Soc. Exp. Biol. Med.</i> 222(2):157-163 (1999)
A26*	Claustre et al., "Conjugation and deamination of circulating dopamine: Relationship between sulfated and free dopamine in man," <i>J. Auton. Nerv. Syst.</i> 29(2):175-182 (1990)
A27*	Coffey et al., "[3H]WIN 35,428 binding to the dopamine uptake carrier. I. Effect of tonicity and buffer composition," <i>J. Neurosci. Methods</i> 51(1):23-30 (1994)
A28	Czarnocki et al. "Enantioselective synthesis of (R)-(-)-Laudanosine and (R)-(-)-Glaucine from L-Ascorbic Acid," <i>Tetrahedron: Assymetry</i> , 7(9):2711-2720 (1996)
A29*	Dandridge et al. <i>J. Med. Chem.</i> 27:28 (1984)
A30*	Diez-Sampedro et al., "Galactose transport inhibition by cytochalasin E in rat intestine in vitro," <i>Can. J. Physiol. Pharmacol.</i> 77(2):96-101 (1999)
A31*	Duport et al., "An in vitro blood-brain barrier model: Cocultures between endothelial cells and organotypic brain slice cultures," <i>Proc. Natl. Acad. Sci. USA</i> 95(4):1840-1845 (1998)
A32*	Earles et al., "Multisubstrate mechanism for the inward transport of dopamine by the human dopamine transporter expressed in HEK cells and its inhibition by cocaine," <i>Synapse</i> 33(3):230-238 (1999)
A33	Fernandez et al., "Synthesis and biological studies of glycosyl dopamine derivatives...", <i>Carbohydr. Res.</i> 327:353-365 (2000)
A34*	Figlewicz, "Endocrine regulation of neurotransmitter transporters," <i>Epilepsy Res.</i> 37(3): 203-210 (1999)

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/625,645
	Filing Date	July 22, 2003
	First Named Inventor	Samual Christian
	Group Art Unit	1623
	Examiner Name	Leigh C. Maier

A35*	Findlay et al., "Inhibition of glycosidases by aldonolactones or corresponding configuration. 2. Inhibitors of b-N-acetylglucosaminidase," <i>Biochemical J.</i> 69:467-476 (1958)
A36*	Fischer et al., "5-Hydroxytryptamine stimulates glucose transport in cardiomyocytes via a monoamine oxidase-dependent reaction," <i>Biochem. J.</i> 311(2):575-583 (1995)
A37*	Fodor et al., <i>Acta Chim. Acad. Sci. Hung.</i> 28(4):409 (1961)
A38*	Freeman et al., "In: Chemical Regulation of Biological Mechanisms", Eds., Crieghton, A.M. and S. Turner. Royal Soc. Chemistry, London. pp 154-165 (1982)
A39*	Gainetdinov et al., "Functional hyperdopaminergia in dopamine transporter knock-out mice," <i>Biol. Psychiatry</i> 46(3):303-311 (1999)
A40*	Gee et al., "Quercetin glucosides interact with the intestinal glucose transporter pathway," <i>Free Radic. Biol. Med.</i> 25(1):19-25 (1998)
A41*	Gerding et al., "Metabolism and disposition of the dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetraline in conscious monkeys after subsequent iv, oral and ocular administration," <i>Drug. Metab. Dispos.</i> 18(6):923-928 (1990)
A42*	Geurts et al., "Assessment of striatal D1 and D2 dopamine receptor-G protein coupling by agonist-induced [35S]GTP gamma S binding," <i>Life Sci.</i> 65(16):1633-1645 (1999)
A43*	Giros et al., "Cloning and functional characterization of a cocaine-sensitive dopamine transporter," <i>FEBS Lett.</i> 295:149-154 (1991)
A44*	Giros et al., "Cloning, pharmacological characterization and chromosome assignment of the human dopamine transporter," <i>Mol. Pharmacol.</i> 42(3):383-390 (1992)
A45	Glinsky et al. Inhibition of colony formation in agarose of metastatic human breast carcinoma and melanoma cells by synthetic glycoamine analogs <i>Clin. Exp. Metastasis</i> 14:253-267 (1996)
A46*	Green et al., "Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein," <i>Drug Metab. Dispos.</i> 24(3):356-363 (1996)
A47*	Haspel et al., "Effects of barbiturates on facilitative glucose transporters are pharmacologically specific and isoform selective," <i>J. Membr. Biol.</i> 169(1):45-53 (1999)
A48*	Hibert et al., "Graphics coputer-aided mapping as a predictive tool for drug design: Development of potent, selective and stereospecific ligands for the 5-HT1A receptor," <i>J. Med. Chem.</i> 31:1087-1093 (1988)
A49*	Horton, "Monosaccharide Amino Sugars. In: "The Amino Sugars": The Chemistry and Biology of Compounds Containing Amino Sugars. Vol. 1A. Ed. R.W. Jeanloz. Academic Press. N.Y. pp. 4-18 (1969)
A50*	Hurtig, "Problems with current treatment of Parkinson's disease," <i>Exper. Neurol.</i> 144:10-16 (1997)
A51*	Husbands et al., "Structure-activity relationships at the monoamine transporters as sigma receptors for a novel series of 9-[3-(cis,5-dimethyl-1-piperazinyl)propyl] carbazole (rmicazole) analogues," <i>J. Med. Chem.</i> 42 (21): 4446-4455 (1999)
A52*	Hyson et al., "Calcium channel blockers modify jejunal uptake of D-galactose in rabbits," <i>Dig. Dis. Sci.</i> 41(9):1871-1875 (1996)
A53*	Hyson et al., "A high cholesterol diet blocks the effect of calcium channel blockers on the uptake of sugars in rabbit intestine," <i>Can. J. Physiol. Pharmacol.</i> 75(1):57-64 (1997)
A54*	Iorio et al., "Benzazepines structure-activity relationships between D1 receptor blockade and selected pharmacological effects," In: <i>Neurobiology of Central D1 Dopamine Receptors</i> , Eds., G.R. Breese and I. Creese, Plenum Press, NY. pp. 1-14 (1986)

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/625,645
	Filing Date	July 22, 2003
	First Named Inventor	Samual Christian
	Group Art Unit	1623
	Examiner Name	Leigh C. Maier

A55*	Jaber et al., "Differential regulation of tyrosine hydroxylase in the basal ganglion of mice lacking the dopamine transporter," <i>Eur. J. Neurosci.</i> 11(10):3499-3511 (1999)
A56	Jakas et al., "Synthesis and CNMR investigation of novel Amadori compounds (1-amino-1-deoxy-D-fructose derivatives) related to the opioid peptide, leucine-enkephalin," <i>J. Chem. Soc., Perkin Trans. 2</i> :789-794 (1996)
A57	Jiang et al., "Dopaminergic properties and experimental anti-Parkinsonian effects...", <i>Clin. Neuropharmacol.</i> 27(2):63-73 (2004)
A58*	Jones et al., "Dopamine neuronal transport kinetics and effects of amphetamine," <i>J. Neurochem.</i> 73(6):2406-2414 (1999)
A59*	Jork et al., "The influence of dopamine on the incorporation of different sugars into total proteins of hippocampal slices," <i>Pharmacol. Biochem. Behav.</i> 13(21):303-304 (1980)
A60*	Kaiser et al., <i>J. Med. Chem.</i> 25:697 (1982)
A61*	Kawasaki et al., "The identification of two N-acyldopamine glucosides in the left colleterial gland of the praying mantid, <i>Tenodera aridifolia sinensis</i> Saussure, and their role in the oothecal sclerotization insect," <i>Biochem.</i> 13:267-271 (1983)
A62*	Kerwin et al., "Negative ion electrospray mass spectrometry of polyphenols, catecholamines and their oxidation products," <i>J. Mass Spectrom.</i> 31:1429-1439 (1996)
A63*	Kerwin, "Profiling peptide adducts of oxidized N-acetyldopamine by electrospray mass spectrometry," <i>Rapid Commun. Mass Spectrom.</i> 11:557-566 (1997)
A64*	Kilbourn et al., "Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice," <i>Synapse</i> 35(4):250-255 (2000)
A65*	Kitty et al., "Cloning and expression of a cocaine-sensitive rat dopamine transporter," <i>Science</i> 254(5031):578-579 (1991)
A66	Knoerzer et al., "Dopaminergic benzo[a]phenanthridines: Resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist," <i>J. Med. Chem.</i> 37:2453-2460 (1994)
A67*	Kuchel, "Peripheral dopamine in hypertension and associated conditions," <i>J. Hum. Hypertens.</i> 13(9):605-615 (1999)
A68*	Kuipers et al., "5-HT1A vs. D2-receptor selectivity of Flesinoxan and analogous N4-substituted and N1-aryl piperazines," <i>J. Med. Chem.</i> 40:300-312 (1997)
A69*	Kumagai, "Glucose transport in brain and retina: Implications in the management and complications of diabetes," <i>Diabetes Metab. Res. Rev.</i> 15(4):261-273 (1999)
A70*	Leal et al., "The metabolism of CGS15873 in man using stable isotope pattern recognition techniques," <i>Biopharm. Drug Dispos.</i> 13(8):617-628 (1992)
A71*	Lichtenthaler, F.W. "Efficient Reaction Channels from Mono- and Disaccharides to Enantiopure Building Blocks and Exploitation of Their Application Profiles" In: <i>Carbohydrates: Synthetic Methods and Applications in Medicinal Chemistry</i> , edited by Ogura, H., Hasegawa, A., and Suami, T. Tokyo: Kodansha, p. 3-27 (1992)
A72*	Liljefors et al., "A molecular mechanics approach to the understanding of presynaptic selectivity for centrally acting dopamine receptor agonists of the phenylpiperidine series," <i>J. Med. Chem.</i> 29:1896 (1986)
A73	Likhoshersfov et al., "Synthesis of N-chloroacetyl-β-glycopyranosylamines, derivatives of monosaccharides and lactose," <i>Russ. Chem. Bl.</i> 45:1760-1763 (1996)
A74	Likhoshersfov et al., <i>Russian Chemical Bulletin</i> , 1998 47(6) page 1214-1217 (abstract)

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<p align="center">INFORMATION DISCLOSURE STATEMENT LIST</p> <p align="center">(Use as many sheets as necessary)</p>	Complete if Known	
	Application Number	10/625,645
	Filing Date	July 22, 2003
	First Named Inventor	Samual Christian
	Group Art Unit	1623
	Examiner Name	Leigh C. Maier

A75*	Lostao et al., "Presence of leptin receptors in rat small intestine and leptin effect on sugar absorption," <i>FEBS Lett.</i> 423(3):302-306 (1998)
A76*	Loland et al., "Defining proximity relationships in the tertiary structure of the dopamine transporter. Identification of a conserved glutamic acid third coordinate in the endogenous Zn ²⁺ binding site," <i>J. Biol. Chem.</i> 274:36928-36934 (1999)
A77	Maher et al., "Substrate specifically and kinetic parameters of GLUT3...", <i>Biochem. J.</i> 315:827-831 (1996)
A78*	Manzi et al., "In: Glycobiology: A Practical Approach," Eds. M. Fukuda and A. Kobata. IRL Press, Oxford University, Oxford. p. 29-31 (1993)
A79*	Martin et al., "Defects in Na ⁺ /glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption," <i>Nat. Genet.</i> 12(2):216-220 (1996)
A80	Mathews et al. Biochemistry. Second Edition. The Benjamin/Cummings Publishing Company, Inc. p. 286 (1996)
A81*	Mattiuz et al., "Disposition and metabolism of olanzapine in mice, dogs and rhesus monkeys," <i>Drug Metab. Dispos.</i> 25(5):573-583 (1997)
A82*	McDermid et al., "Enantioselective binding of (+) and (-) 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes and related agonists to dopamine receptors," In: Catecholamines: Basic and Clinical Frontiers, Eds., E. Usdin, I.J. Kopin and J. Barchas, Pergamon Press, NY. p. 568-570 (1978)
A83	Meiergerd et al., "Striatal transporter for dopamine...", <i>J. Neurochem.</i> 62(3):998-1008 (1994)
A84*	Melikian et al., "Membrane trafficking regulates the activity of the human dopamine transporter," <i>J. Neurosci.</i> 19(18):7699-7710 (1999)
A85	The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals, 13th Edition 447 1 (Maryadele J. O'Neil et al. Eds. 2001)
A86*	Meyer et al., "Pharmacokinetics and first clinical experiences with an antihypertensive dopamine (DA ₂) agonist," <i>Eur. Heart J.</i> 13(Suppl. D):121-128 (1992)
A87*	Mico et al., "Function-group metabolism of dopamine-2 agonists: Conversion of 4-(2-di-N-propylaminoethyl)-2-(3H)-indolone to 4-(2-di-N-propylaminoethyl)-7-hydroxyl-2-(3H)-indolone," <i>J. Pharm. Sci.</i> 75(10):929-933 (1986)
A88*	Miller et al., "Dopamine transporters and neuronal injury," <i>Trends Pharmacol. Sci.</i> 20(10): 424-429 (1999)
A89*	Minor et al., "Synthesis and molecular modeling of 1-phenyl-1,2,3,4-tetrahydroisoquinolines and related 5,6,8,9-tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 dopamine antagonists," <i>J. Med. Chem.</i> 37:4317-4328 (1994)
A90*	Mizuma et al., "The beta-anomeric and glucose preferences of glucose transport carrier for intestinal active absorption of monosaccharide conjugates," <i>Biochim. Biophys. Acta</i> 1200(2):117-122 (1994)
A91	Mizuma et al., "Intestinal active absorption of sugar-conjugated compounds by glucose transport system: Implications for improvement of poorly absorbable drugs," <i>Biochem. Pharmacol.</i> 43:2037-2039 (1992)
A92	Mizuma et al., "Comparative study of active absorption by the intestine and disposition of anomers of sugar-conjugated compounds," <i>Biochem. Pharmacol.</i> 45(7):1520-1523 (1993)
A93*	Morgan et al., "N-b-Alanylnorepinephrine: Biosynthesis in insect cuticle and possible role in sclerotization," <i>Insect Biochem.</i> 17: 255-263 (1987)

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/625,645
	Filing Date	July 22, 2003
	First Named Inventor	Samual Christian
	Group Art Unit	1623
	Examiner Name	Leigh C. Maier

A94*	Morgan et al., "Dopamine receptor subtypes and formalin test analgesia," <i>Pharmacol. Biochem. Behav.</i> 40(2):317-322 (1991)
A95*	Mueller et al., "1H and 13C NMR of 3-0 and 40 conjugates of dopamine and other catecholamines," <i>Bioconjug. Chem.</i> 4(1):47-53 (1993)
A96*	Navarro et al., "Effect of erythromycin on D-galactose absorption and sucrase activity in rabbit jejunum," <i>Can. J. Physiol. Pharmacol.</i> 71(3-4):191-194 (1993)
A97	Ohnishi et al. <i>J. Drug. Targeting</i> (2000)
A98	Ovalle et al., "Systematic analysis of oxidative degradation...", <i>Carbohydr. Res.</i> 330:131-139 (2000)
A99*	Petersson et al., "Conformational analysis and structure-activity relationships of selective dopamine D1 receptor agonists and antagonists of the benzazepine series," <i>J. Med. Chem.</i> 33:2197-2204 (1990)
A100*	Pokorski et al., "Fatty acid acylation of dopamine in the carotid body," <i>Med. Hypothesis.</i> 50(2):131-133 (1998)
A101*	Pocchiari et al., "Ibopamine, an orally active dopamine-like drug: Metabolism and pharmacokinetics in rats," <i>Arzneim. -Forsch.</i> 36(2A):334-340 (1986)
A102*	Prakash et al., "Metabolism and excretion of a new anxiolytic drug candidate, CP-93,393, in healthy male volunteers," <i>Drug Metab. Dispos.</i> 26(5):448-456 (1998)
A103*	Prakash et al., "N-phenylalkyl-substituted tropane analogs of boat conformation of high selectivity for the dopamine versus serotonin transporter," <i>Bioorg. Med. Chem. Lett.</i> 9 (23):3325-3328 (1999)
A104*	Ramaswamy et al., "1-0-acyl derivatives of glucose as non-penetrating inhibitors of glucose transport by hamster small intestine in vitro," <i>Biochim. Biophys. Acta</i> 443:284-287 (1976)
A105*	Rhoads et al., "Circadian periodicity of intestinal Na ⁺ /glucose cotransporter 1 mRNA levels is transcriptionally regulated," <i>J. Biol. Chem.</i> 273(16):9510-9516 (1998)
A106*	Riggs et al., "Specific dopamine D-1 and DA1 properties of 4-(mono- and dihydroxyphenyl) -1,2,3,4-tetrahydroisoquinoline and its tetrahydrothieno [2,3-c] pyridine analogue," <i>J. Med. Chem.</i> 30:1454-1458 (1987)
A107	Roper et al., "NMR spectroscopy of N-(1-deoxy-D-fructos-1-YL)-L-amino acids ("fructose-amino acids)," <i>Carb. Res.</i> 116:183-195 (1983)
A108*	Schauer, "In: Methods in Enzymology," Ed. V. Ginsberg. Academic Press, NY. p. 64-89 (1978)
A109*	Seiler et al., "Further characterization of structural requirements for agonists at the striatal dopamine D-1 receptor. Studies with a series of monohydroxyaminotetralins on dopamine-sensitive adenylate cyclase and comparison with dopamine receptor binding," <i>Mol. Pharmacol.</i> 22:281-289 (1982)
A110*	Seiler et al., "Characterization of dopamine receptor subtypes by comparative structure-activity relationships: dopaminomimetic activities...", <i>J. Mol. Pharmacol.</i> 35:643-651 (1989)
A111*	Seiler et al., "Trans-Hexahydroindolo[4,3-ab]phenanthridines ("Benzergolines"), the first structural class of potent and selective D1 receptor agonists lacking a catechol group," <i>J. Med. Chem.</i> 34(1):3113-3117 (1991)
A112*	Shimada et al., "Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. <i>Science</i> 254(5031):576-578 (1991)

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/625,645
	Filing Date	July 22, 2003
	First Named Inventor	Samual Christian
	Group Art Unit	1623
	Examiner Name	Leigh C. Maier

A113*	Shindo et al., "Metabolism of D- and L-isomers of 3,4 dihydroxyphenylalanine (DOPA). V. Mechanism of intestinal absorption of carbon-14 labeled D- and L-dopa in rats," <i>Chem. Pharm. Bull.</i> 21(9):2031-2038 (1973)
A114*	Shah et al., "(+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: Novel dopamine D1 receptor antagonists," <i>J. Med. Chem.</i> 39:3423-3428 (1996)
A115	Shukla et al., "Effect of desoxy-fructose derivatives of dopa and dopamine on body temperature," <i>Archiv für Arzneitherapie</i> 5(1):183-195 (1981)
A116*	Snyder et al., "Synthesis and evaluation of 6,7-dihydroxy-2,3,4,8,9,13b-hexahydro1H-benzo[6,7]cycloheptal [1,2,3ef][3]benzazepine, 6,7-dihydroxy-2,3,4,8,9,12b-hexahydroanthra-[10,4a,4-c,d]azepine and 10-(aminomethyl)- 9,10-dihydro-1,2-dihydroxyanthracene as conformationally restricted analogs of b-phenyldopamine," <i>J. Med. Chem.</i> 38:2395-2409 (1995)
A117*	Storch et al., "HEK-293 cells expressing the human dopamine transporter are susceptible to low concentrations of 1-methyl-4-phenylpyridine acting via impairment of energy metabolism," <i>Neurochem. Int.</i> 35(5):393-403 (1999)
A118*	Sugamori et al., "A cognate dopamine transporter-like activity endogenously expressed in a COS-7 kidney derived cell line," <i>FEBS Lett.</i> 451(2):169-174 (1999)
A119	Tamai et al., "Transporter-mediated permeation of drugs...", <i>J. Pharm. Sci.</i> 89(11):1371-1388 (2000)
A120	Takata et al., "Transport of glucose across the blood-tissue barriers," <i>Int. Rev. Cytology</i> 172:1-53 (1997)
A121	Tarjanyi et al., "Chromatographic investigation and computer simulation of (-)deprenyl metabolism," <i>New Approaches Chromatog.</i> 243-266 (1993)
A122*	Umegae et al., <i>Anal. Chim. Acta</i> 208:59 (1988)
A123*	van de Waterbeemd et al., "Quantitative structure-activity relationships and eudismic analyses of the presynaptic dopaminergic...", <i>J. Med. Chem.</i> 30:2175 (1987)
A124*	Vandenbergh et al., "A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs," <i>Brain Res. Mol. Brain Res.</i> 15(1-2):161-166 (1992)
A125	Vannucci et al., "Glucose transporter expression in brain: Relationship to cerebral glucose utilization," <i>Dev. Neurosci.</i> 20(4-5):369-379 (1998)
A126*	Verhoeff et al., "Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders," <i>Psychopharmacol. (Berl)</i> 147(3):217-249 (1999)
A127*	Wang et al., "Conjugation patterns of endogenous plasma catecholamines in human and rat," <i>J. Lab. Clin. Med.</i> 101(1):141-151 (1983)
A128*	Wang et al., "Catecholamine glucuronidation: An important metabolic pathway for dopamine in the rat," <i>J. Neurochem.</i> 40(5):1435-1440 (1983)
A129*	Weinstock et al., <i>Drugs Future</i> 10:645 (1985)
A130*	Whitfield et al., "Acceleration of sugar transport in avian erythrocytes by catecholamines," <i>J. Biol. Chem.</i> 249(13):4181-4188 (1974)
A131*	Wright et al., "Regulation of Na ⁺ /glucose cotransporters," <i>J. Exp. Biol.</i> 200(2):287-293 (1997)
A132*	Wu et al., "Molecular cloning of the mouse dopamine transporter and pharmacological comparison with the human homologue," <i>Gene</i> 233(1):163-170 (1999)

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/625,645
	Filing Date	July 22, 2003
	First Named Inventor	Samual Christian
	Group Art Unit	1623
	Examiner Name	Leigh C. Maier

	A133	Wunder et al., "Enhanced albumin uptake by rat tumors," <i>Int. J. Oncol.</i> 11:497-507 (1997)
Examiner Signature:		Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	